Boyd, Mark A and Dixit, Narendra M and Siangphoe, Umaporn and Buss, Neil E and Salgo, Miklos P and Lange, Joep MA and Phanuphak, Praphan and Cooper, David A and Perelson, Alan S and Ruxrungtham, Kiat (2006) Viral Decay Dynamics in HIV-Infected Patients Receiving Ritonavir-Boosted Saquinavir and Efavirenz With or Without Enfuvirtide: A Randomized, Controlled Trial (HIV-NAT 012). In: Journal of Infectious Diseases, 194 . pp. 1319-1322.
Restricted to Registered users only
Download (258Kb) | Request a copy
The availability of enfuvirtide enables assessment of whether human immunodeficiency virus (HIV) decay can be enhanced by targeting reverse transcriptase, protease, and fusion. We performed a 12-week study of 22 patients randomized to receive ritonavir-boosted saquinavir and efavirenz with (the 3-target arm) or without (the 2-target arm) enfuvirtide. We observed no difference in the mean \pm SD elimination-rate constant for overall decay ( 0.142 \pm 0.040 per day and 0.128 \pm 0.033 per day in the 2- and 3-target arms, respectively; P>.1) or for modeled first-phase decay rate ( -0.62 \pm 0.34 per day and -0.51 \pm 0.16 per day; P >.1). Antiretroviral therapy that inhibits HIV reverse transcriptase and protease exerts potent antiviral effects that might not be augmented by the addition of an HIV fusion inhibitor.
|Item Type:||Journal Article|
|Additional Information:||Copyright of this article belongs to University of Chicago Press.|
|Department/Centre:||Division of Mechanical Sciences > Chemical Engineering|
|Date Deposited:||29 May 2008|
|Last Modified:||19 Sep 2010 04:45|
Actions (login required)